Paradigm new target $ 5.50, from $ 4.60Interesting data: PBI4050 Outperforms Many Competitors The average reduction in HbA1c seen in this trial compares favourably to many other antidiabetic drugs currently on the market (Figure 2). The preliminary results show 4050 outperforming industry-leader Sitagliptin 100, which showed a reduction of 0.56